Genetically Elevated Serum Uric Acid and Renal Function in an Apparently Healthy Population

2019 ◽  
Vol 104 (3-4) ◽  
pp. 277-282
Author(s):  
Ji-Yong Ge ◽  
Yuan Ji ◽  
Zhen-Yan Zhu ◽  
Xun Li
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Elevated Serum ◽  
Healthy Population ◽  
Apparently Healthy

SAT0374 Elevated Serum Homocysteine Levels in Gouty Patients were Related Not with Serum Uric Acid Levels but with Decreased Renal Function

2013 ◽  
Vol 72 (Suppl 3) ◽  
pp. A710.2-A710
Author(s):  
J. S. Kim ◽  
S. T. Choi ◽  
J.-S. Song ◽  
E.-J. Kang ◽  
K.-H. Lee ◽  
...  
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Elevated Serum ◽  
Serum Homocysteine

The relationship between elevated serum uric acid and arterial stiffness in a healthy population

Vascular ◽  
2020 ◽  
Vol 28 (4) ◽  
pp. 494-501 ◽  
Author(s):  
Ye Jiang ◽  
Ji-Yong Ge ◽  
Yu-Yan Zhang ◽  
Fang-Fang Wang ◽  
Yuan Ji ◽  
...  
Keyword(s):  
Uric Acid ◽  
Arterial Stiffness ◽  
Serum Uric Acid ◽  
Elevated Serum ◽  
Healthy Population ◽  
Diabetic Mellitus ◽  
The Relationship ◽  
Circulating Levels ◽  
Randomization Method

Objective This study aims to investigate the relationship between serum uric acid and arterial stiffness in a healthy population. Methods Among the 979 participants, baPWV was non-invasively measured, the circulating levels of uric acid were tested, and the uric acid polymorphisms (rs2231142 and rs11722228) were genotyped. Then, the Mendelian randomization method was employed to test the relationship between serum uric acid and arterial stiffness in a healthy population. Results After adjusting for age, gender, antihypertensive medication, body mass index, waist-to-hip ratio, urea nitrogen, creatinine and diabetic mellitus, there was a significant allelic difference in uric acid levels for each genotype ( P <  0.0001 for rs2231142; P =  0.007 for rs11722228). However, there were no differences on the potential confounders between the genotypes of rs2231142 and rs11722228 ( P >  0.05). The baPWV was significantly associated with circulating levels of uric acid after adjusting for cardiovascular risk factors and other potential confounders ( P =  0.002). However, neither the single polymorphism, nor the accumulation of culprit alleles was associated with baPWV ( P =  0.92 for rs2231142; P =  0.60 for rs11722228; P for trend = 0.77 for the combined analysis of culprit alleles). Conclusion These results do not support the causal role of circulating levels of uric acid in the development of arterial stiffness.

scholarly journals Hyperuricemia and Hypertension, Coronary Artery Disease, Kidney Disease: From Concept to Practice

2020 ◽  
Vol 21 (11) ◽  
pp. 4066 ◽  
Author(s):  
Mélanie Gaubert ◽  
Thomas Bardin ◽  
Alain Cohen-Solal ◽  
François Diévart ◽  
Jean-Pierre Fauvel ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Renal Function ◽  
Uric Acid ◽  
Coronary Artery ◽  
Kidney Disease ◽  
Serum Uric Acid ◽  
Elevated Serum ◽  
Renal Diseases ◽  
Increased Risk ◽  
Artery Disease

Since the publication of the Framingham Heart Study, which suggested that uric acid should no longer be associated with coronary heart disease after additional adjustment for cardiovascular disease risk factors, the number of publications challenging this statement has dramatically increased. The aim of this paper was to review and discuss the most recent studies addressing the possible relation between sustained elevated serum uric acid levels and the onset or worsening of cardiovascular and renal diseases. Original studies involving American teenagers clearly showed that serum uric acid levels were directly correlated with systolic and diastolic pressures, which has been confirmed in adult cohorts revealing a 2.21-fold increased risk of hypertension. Several studies involving patients with coronary artery disease support a role for serum uric acid level as a marker and/or predictor for future cardiovascular mortality and long-term adverse events in patients with coronary artery disease. Retrospective analyses have shown an inverse relationship between serum uric acid levels and renal function, and even a mild hyperuricemia has been shown to be associated with chronic kidney disease in patients with type 2 diabetes. Interventional studies, although of small size, showed that uric acid (UA)-lowering therapies induced a reduction of blood pressure in teenagers and a protective effect on renal function. Taken together, these studies support a role for high serum uric acid levels (>6 mg/dL or 60 mg/L) in hypertension-associated morbidities and should bring awareness to physicians with regards to patients with chronic hyperuricemia.

scholarly journals Role of elevated serum uric acid levels at the onset of overt nephropathy in the risk for renal function decline in patients with type 2 diabetes

2014 ◽  
Vol 6 (1) ◽  
pp. 98-104 ◽  
Author(s):  
Kentaro Tanaka ◽  
Shigeko Hara ◽  
Masakazu Hattori ◽  
Ken Sakai ◽  
Yukiko Onishi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Elevated Serum ◽  
Overt Nephropathy ◽  
Renal Function Decline

Serum Heme Oxygenase-1 Level is Increased in Cardiac Patients with Elevated Serum Uric Acid and Decreased Renal Function

2014 ◽  
Vol 20 (10) ◽  
pp. S164
Author(s):  
Shuichi Fujita ◽  
Shun Kizaka ◽  
Hideaki Morita ◽  
Takahide Ito ◽  
Kazushi Sakane ◽  
...  
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Heme Oxygenase ◽  
Elevated Serum ◽  
Cardiac Patients ◽  
Heme Oxygenase 1

scholarly journals SAT0507 CLINICAL CHARACTERISTICS AND TREATMENT RESPONSE IN JUVENILE GOUT PATIENTS: A SINGLE CENTER EXPERIENCE

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1210.2-1210
Author(s):  
S. Zheng ◽  
P. Y. Lee ◽  
Y. Huang ◽  
Q. Huang ◽  
S. Chen ◽  
...  
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Treatment Response ◽  
Serum Uric Acid ◽  
Clinical Characteristics ◽  
Disease Onset ◽  
Clinical Manifestations ◽  
Joint Involvement ◽  
Normal Body Mass Index ◽  
Finger Joints

Background:The incidence of juvenile gout is increasing in China. The clinical manifestations of juvenile gout and treatment strategies to reduce uric acid levels in children are not well described due to the limited number of cases in the past.Objectives:We aim to describe the clinical characteristic of children with gout and study the treatment response to febuxostat.Methods:These studies were approved by the Institutional Review Board of Guangdong Second provincial General Hospital. We performed a retrospective analysis on 98 juvenile gout patients (age ≤ 18 years) evaluated in our hospital from Jan 2016 to Dec 2019. We analyzed clinical parameters, laboratory data and treatment response.Results:The average age of disease onset in children with gout was 15.2 ± 2.0 years and the youngest patient was 9 years old. The majority of patients were male (94/98) and mean serum uric acid (sUA) level were 705.8 ± 145.7 μmol/L (reference range <420 μmol/L). More than half of the cohort had normal body mass index (mean 24.7 ± 4.7 kg/m2; range 14.9 to 36.1 kg/m2). Renal function was generally normal in these children (serum creatinine 96.9 ± 17.8 μmol/L). In terms of joint manifestations, juvenile gout preferentially affected finger joints (29%), ankles (28%) and metatarsal joints (MTP; 20%). The most frequent sites of initial gout attack were ankles (45%), MTP (39%) and fingers (6%). In addition, tophi can occur in pediatric patients and typically develop in the finger joints (54%). Tophi was observed in about 25% of juvenile gout patients, typically within the first two years of disease onset (mean duration 1.7 ± 0. 9 years). We have found tophi in children as young as 10 years of age.For treatment for chronic hyperuricemia, 32 patients (32.7%) were started on febuxostat and 5 patients (5.1%) received allopurinol. A decrease in sUA was observed in both groups after the first month of treatment (febuxostat: baseline 690.4 ± 99.7 μmol/L to 482.7 ± 140.8 μmol/L vs. allopurinol: baseline 728.8 ±112.8 μmol/L to 565.0 ± 116.7 μmol/L, P=0.477). Serum uric acid of 6 patients in the febuxostat group (none in the allopurinol group) dropped below 360 μmol/L. There were no statistical differences in Cr, AST and ALT between the groups. During follow-up after 3 months, further decline in sUA level were observed in patients treated with febuxostat (409.5 ± 83.4, compared with baseline P<0.001).Conclusion:Juvenile gout has a different pattern of joint involvement and is less associated with elevated BMI compared to gout in adults. We show that febuxostat is effective in reducing uric acid levels in juvenile gout. These findings will help clinicians better understand the clinical manifestations and treatment response in juvenile gout.Figure 1Compared treatment response with allopurinol and febuxostatReferences:[1]Kishimoto K, Kobayashi R, Hori D, et al. Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. Anticancer Res. 2017 Oct;37(10):5845-5849.[2]Lu, C.C., et al. Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout. J Rheumatol, 2014. 41(9): p. 1878-83.Disclosure of Interests:None declared

Chlorogenic acid supplementation ameliorates hyperuricemia, relieves renal inflammation, and modulates intestinal homeostasis

2021 ◽  
Author(s):  
Xiaofei Zhou ◽  
Bowei Zhang ◽  
Xiuli Zhao ◽  
Yongxi Lin ◽  
Jin Wang ◽  
...  
Keyword(s):  
Uric Acid ◽  
Chlorogenic Acid ◽  
Serum Uric Acid ◽  
Inflammatory Responses ◽  
Elevated Serum ◽  
Purine Metabolism ◽  
Intestinal Homeostasis ◽  
Renal Inflammation ◽  
Acid Supplementation

Hyperuricemia (HUA) is induced by abnormal purine metabolism and elevated serum uric acid (UA) concentrations, and it is often accompanied by inflammatory responses and intestinal disorders. This study aims to...

Sign in / Sign up

Export Citation Format

Share Document